US Stock Insider Trading | Fortrea Holdings disclosed 4 insider transactions on February 11

K-LinePoet · 2026-02-24T06:10:48+00:00

Fortrea Holdings disclosed insider trading activities on February 11, 2026, including Morais Mark A. selling 590 shares, and McConnell Jill G. selling 441 shares and 440 shares, with total amounts of $8,324.90 and $6,222.51 respectively. The company was established in 2023 and is a global leading contract research organization.

K-LinePoet

2026-02-24 06:10:48

Abstract generation in progress

On February 11, 2026, Fortrea Holdings (FTRE) disclosed four insider trades. Executive Morais Mark A. sold 590 shares on February 10, 2026.

【Recent Insider Trades】

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 11, 2026	Executive	McConnell Jill G.	February 10, 2026	Sell	441	14.11	6,222.51
February 11, 2026	Executive	McConnell Jill G.	February 10, 2026	Sell	440	13.65	6,006.00
February 11, 2026	Executive	Morais Mark A.	February 10, 2026	Sell	590	14.11	8,324.90
February 11, 2026	Executive	Morais Mark A.	February 10, 2026	Sell	589	13.65	8,039.85
September 17, 2025	Executive	Parks Robert	September 16, 2025	Sell	7,338	9.95	$73,000
September 10, 2025	Executive	McConnell Jill G.	September 9, 2025	Sell	3,156	10.23	$32,300
September 10, 2025	Executive	Morais Mark A.	September 9, 2025	Sell	3,155	10.23	$32,300
September 10, 2025	Executive	Parks Robert	September 9, 2025	Sell	592	10.23	$6,056.16
September 10, 2025	Executive	Hanson James S.	September 9, 2025	Sell	1,677	10.23	$17,200
September 4, 2025	Director	Russell Erin L	September 2, 2025	Buy	9,854	10.15	$100,000

【Company Profile】

Fortrea Holdings Inc. was incorporated in Delaware on January 31, 2023. The company is a leading global Contract Research Organization (CRO) providing clinical development, patient access solutions, and consulting services to the life sciences industry. The company offers Phase I to IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions, and post-approval services.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.